Aaron Mammoser
Neurology · Atlanta, GANPI 1164549895
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by AstraZeneca at 58.0% of the total. 2025 is the largest year on record at $2,144, 4.9 times the $440 reported in 2019.
Across 30 payments — averaging $114.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novocure Inc.$549
- GT Medical Technologies, Inc$221
- Terumo BCT, Inc.$122
- Longeviti Neuro Solutions Inc$116
- Globus Medical$115
- plus $325 from 9 others
Across 29 payments — averaging $1541.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$25K
- Novocure GmbH$20K
What the payments were for
- Consulting fees$1,95057%
- Food & beverage$1,49743%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $1,998 |
| Novocure Inc. | 10 | $549 |
| GT Medical Technologies, Inc | 2 | $221 |
| Terumo BCT, Inc. | 1 | $122 |
| Longeviti Neuro Solutions Inc | 1 | $116 |
| Globus Medical | 1 | $115 |
| E.r. Squibb & Sons, L.L.C. | 1 | $81 |
| UCB, Inc. | 3 | $53 |
| Brainlab, Inc. | 1 | $49 |
| Amgen | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Caris MPI, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Day One Biopharmaceuticals | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KOSELUGO$1,950
- GammaTile$172
- Bone Marrow Aspirate Concentrate System$122
- CLEARFIT$116
- InvisiShunt Implant Kit$116
- Excelsius - GPS$115
- Oncology$103
How this compares
$3,447 in reported general payments places this provider in the 60th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 89 | $3,399 |
| Dexamethasone | 42 | $1,201 |
| Lacosamide | 11 | $984 |
| Gabapentin | 27 | $357 |
| Nortriptyline Hcl | 12 | $309 |
| Fluoxetine Hcl | 16 | $224 |
| Famotidine | 15 | $187 |
| Duloxetine Hcl | 11 | $158 |
| Ondansetron Hcl | 23 | $140 |
| Trazodone Hcl | 16 | $42 |
Paid to pharmacies, not to this prescriber.
Other neurology in Atlanta
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Robert GilbertAtlanta$412K
- Lawrence SeidenAtlanta$272K
- Jacqueline RosenthalAtlanta$241K
- Ben ThrowerAtlanta$203K
- Jaime Hatcher MartinAtlanta$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.